IL-6 signaling, lung injury, and post-TB lung disease in TB/HIV
Official title: Interleukin-6 signaling, lung injury, and post-TB lung disease in TB-HIV
Funded at Boston University Medical Campus · NIH-11604270 · Data updated 2026-11-12
This grant tests how a specific immune signal (IL-6) relates to lung damage after tuberculosis in people with and without HIV, aiming to understand who is at risk for lasting lung problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $83,562 |
| NIH project number | 3R01AI184179-03S2 |
| Project ID | NIH-11604270 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with drug-sensitive TB, with and without HIV, who are starting TB treatment and followed through and after completion.
✕Less likely to help
Patients not enrolled in TB treatment programs or those with non-drug-sensitive TB may have different risks and may not directly benefit.
What this research studies
This project follows people with drug-sensitive TB to see how their lungs recover after treatment and whether IL-6 pathways influence the extent of lung injury. It uses a multi-site design in India to compare HIV-uninfected and HIV-infected TB patients under the same protocol. Researchers will collect clinical data, imaging, and biological samples over time to map the burden and patterns of post-TB lung disease. Findings could point toward future interventions to reduce long-term lung disability in TB survivors, including those living with HIV.
Why it matters
Potential benefit: If successful, the work could lead to strategies to prevent or lessen long-term lung damage in TB patients, especially those with HIV.
How similar studies have gone: Previous studies have described post-TB lung disease, but direct links to IL-6 signaling and comparative HIV status are still being explored.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Gupte, Akshay Nitin — Boston University Medical Campus
- Study coordinator: Gupte, Akshay Nitin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.